Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Jian Lun Xu"'
Autor:
Jian-Lun Xu
Publikováno v:
Contemporary Experimental Design, Multivariate Analysis and Data Mining ISBN: 9783030461607
When a \(p\times 1\) random vector \(\mathbf{X}\) has a spherically symmetric distribution with the location vector \({\varvec{\theta }},\) Brandwein and Strawderman [7] proved that estimators of the form \(\mathbf{X}+a\mathbf{g}(\mathbf{X})\) domina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f93ea8b3d7ed95752d748d54b214ab5d
https://doi.org/10.1007/978-3-030-46161-4_13
https://doi.org/10.1007/978-3-030-46161-4_13
Publikováno v:
Biometrics. Sep2004, Vol. 60 Issue 3, p651-660. 10p. 4 Charts.
Autor:
Edward E. Partridge, Thomas L. Riley, Jian Lun Xu, John Commins, Philip C. Prorok, Christine Cole Johnson, Saundra S. Buys
Publikováno v:
Gynecologic Oncology. 125:70-74
Objective To determine whether CA-125 velocity is a statistically significant predictor of ovarian cancer and develop a classification rule to screen for ovarian cancer. Methods In the ovarian component of the PLCO cancer screening trial, 28,038 wome
Autor:
E. David Crawford, Gerald L. Andriole, Douglas J. Reding, Timothy R. Church, Barnett S. Kramer, David Chia, Aimée R. Kreimer, Edward P. Gelmann, Jian Lun Xu, Stuart G. Baker, Jonathan D. Clapp, Christine D. Berg, Robert E. Schoen, Thomas L. Riley, John K. Gohagan, Phil C. Prorok, Mona N. Fouad, Lois Lamerato, Richard M. Fagerstrom, Jennifer M. Croswell
Publikováno v:
The Annals of Family Medicine. 7:212-222
PURPOSE Multiple cancer screening tests have been advocated for the general population; however, clinicians and patients are not always well-informed of screening burdens. We sought to determine the cumulative risk of a false-positive screening resul
Autor:
Bruce Kessel, Saundra S. Buys, Joel L. Weissfeld, Craig Williams, Gerald L. Andriole, Claudine Isaacs, Jian Lun Xu, Robert T. Greenlee, Christine Cole Johnson, Aimée R. Kreimer, Edward E. Partridge, Lawrence R. Ragard, Timothy R. Church, Sheryl L. Ogden
Publikováno v:
Obstetrics & Gynecology. 113:775-782
To test whether annual screening with transvaginal ultrasonography and CA 125 reduces ovarian cancer mortality.Data from the first four annual screens, denoted T0-T3, are reported. A CA 125 value at or above 35 units/mL or an abnormality on transvagi
Autor:
Craig Williams, Bruce Kessel, Thomas L. Riley, Saundra S. Buys, Lawrence R. Ragard, Christine Cole Johnson, Jian Lun Xu
Publikováno v:
Gynecologic Oncology. 110:383-389
To determine the epidemiology of CA-125 in women without ovarian cancer.We analyzed demographic, medical and lifestyle characteristics related to CA-125, measured using the Centocor CA-125II RIA assay, among 25,608 multi-ethnic U.S. women aged 55-74
Autor:
Jian-Lun Xu
Publikováno v:
Journal of Statistical Planning and Inference. 137:1161-1172
Let X and Y be two competing lifetimes with continuous survival functions F ¯ ( t ) and G ¯ ( t ) , respectively, and let β be a nonnegative random variable with B ( b ) = P [ β ⩽ b ] . A generalized proportional hazards model proposed by Pena
Autor:
Jian-Lun Xu, Grant Izmirlian
Publikováno v:
Journal of Multivariate Analysis. 97(2):514-525
Estimation of the location parameters of a p×1 random vector X̲ with a spherically symmetric distribution is considered under quadratic loss. The conditions of Brandwein and Strawderman [Ann. Statist. 19(1991) 1639–1650] under which estimators of
Autor:
Philip C. Prorok, Jian-Lun Xu
Publikováno v:
Statistics in Medicine. 22:2401-2416
Correlated binary data occur very frequently in cluster sample surveys, dependent repeated cancer screening, teratological experiments, ophthalmologic and otolaryngologic studies, and other clinical trials. The standard methods to analyse these data
Estimation of post-lead-time survival under dependence between lead-time and post-lead-time survival
Publikováno v:
Statistics in Medicine. 18:155-162
Early detection of cancer by screening advances the date of diagnosis, but may or may not alter time to death. Screening programme need to assess the true benefit of screening, that is, the length of time by which survival has been extended, beyond m